Company Details
gilead-sciences
14,615
738,160
541714
gilead.com
245
GIL_6922720
Completed

Gilead Sciences Company CyberSecurity Posture
gilead.comAt Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Company Details
gilead-sciences
14,615
738,160
541714
gilead.com
245
GIL_6922720
Completed
Between 750 and 799

Gilead Sciences Global Score (TPRM)XXXX

Description: On **April 2, 2025**, the **Maine Office of the Attorney General** disclosed a **data breach** involving **Gilead Sciences, Inc.**, stemming from an **inadvertent mailing error** by **Billing Document Specialists**. The incident, detected on **February 18, 2025**, resulted in the **unauthorized disclosure of sensitive personal information**—specifically **Social Security numbers**—of **12,224 individuals**, including **4 residents in California**. The breach occurred due to a **procedural failure in handling physical mail**, leading to the exposure of **confidential financial identifiers** without evidence of malicious cyber activity or further exploitation. While the exposed data carries **high sensitivity**, there were **no reports of identity theft, financial fraud, or systemic compromise** linked to the incident. The company likely initiated **remediation measures**, such as notifications to affected parties and regulatory bodies, but the breach’s scope remained **contained to document mishandling** rather than a targeted cyberattack or systemic vulnerability exploitation.
Description: The employees of drugmaker company Gilead Sciences were targeted by some hackers linked to Iran. The web domains and hosting servers and fake email logins were used to compromise the company's servers.


Gilead Sciences has 49.25% more incidents than the average of same-industry companies with at least one recorded incident.
Gilead Sciences has 29.87% more incidents than the average of all companies with at least one recorded incident.
Gilead Sciences reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 0 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.
Gilead Sciences cyber incidents detection timeline including parent company and subsidiaries

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to eac

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions s
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our pr

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in v
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research,
.png)
Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?
Robust product sales and significant increase in net income highlight Gilead's financial resilience.Strategic partnerships and acquisitions...
Here's why analysts believe Gilead Sciences (NASDAQ: GILD) could see about 3% upside by 2027, driven by steady HIV growth, new drug launches...
Oversubscribed $500M Placement: In late Sept 2025 QCi closed a private placement of 26.87 million shares at market price, raising ~$500...
Generic drugmaker Lupin has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application...
These are the stocks posting the largest moves in midday trading.
The S&P 500 came within a hair of a new high, while the Dow Jones Industrial Average still has yet to hit a fresh peak in 2025.
With Black women and straight men increasingly at risk, Gilead's Yeztugo may finally offer a discreet, stigma-free way to stop the spread of...
Gilead invests in world-class science and is pursuing innovation across the therapeutic areas of virology, oncology and inflammation.

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of Gilead Sciences is http://www.gilead.com.
According to Rankiteo, Gilead Sciences’s AI-generated cybersecurity score is 799, reflecting their Fair security posture.
According to Rankiteo, Gilead Sciences currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, Gilead Sciences is not certified under SOC 2 Type 1.
According to Rankiteo, Gilead Sciences does not hold a SOC 2 Type 2 certification.
According to Rankiteo, Gilead Sciences is not listed as GDPR compliant.
According to Rankiteo, Gilead Sciences does not currently maintain PCI DSS compliance.
According to Rankiteo, Gilead Sciences is not compliant with HIPAA regulations.
According to Rankiteo,Gilead Sciences is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Gilead Sciences operates primarily in the Biotechnology Research industry.
Gilead Sciences employs approximately 14,615 people worldwide.
Gilead Sciences presently has no subsidiaries across any sectors.
Gilead Sciences’s official LinkedIn profile has approximately 738,160 followers.
Gilead Sciences is classified under the NAICS code 541714, which corresponds to Research and Development in Biotechnology (except Nanobiotechnology).
Yes, Gilead Sciences has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/gilead-sciences.
Yes, Gilead Sciences maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/gilead-sciences.
As of December 11, 2025, Rankiteo reports that Gilead Sciences has experienced 2 cybersecurity incidents.
Gilead Sciences has an estimated 4,470 peer or competitor companies worldwide.
Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.
Detection and Response: The company detects and responds to cybersecurity incidents through an communication strategy with public disclosure via maine office of the attorney general..
Title: Cyber Attack on Gilead Sciences by Iran-Linked Hackers
Description: The employees of drugmaker company Gilead Sciences were targeted by some hackers linked to Iran. The web domains and hosting servers and fake email logins were used to compromise the company's servers.
Type: Cyber Attack
Attack Vector: Phishing, Server Compromise
Threat Actor: Iran-Linked Hackers
Title: Gilead Sciences, Inc. Data Breach via Mailing Error
Description: The Maine Office of the Attorney General reported a data breach involving Gilead Sciences, Inc. The breach occurred due to an inadvertent disclosure of 12,224 individuals' information, including Social Security numbers, through a mailing error by Billing Document Specialists. The incident affected 4 residents in California.
Date Detected: 2025-02-18
Date Publicly Disclosed: 2025-04-02
Type: Data Breach
Attack Vector: Human Error (Mailing Error)
Common Attack Types: The most common types of attacks the company has faced is Breach.
Identification of Attack Vectors: The company identifies the attack vectors used in incidents through Fake Email Logins.

Systems Affected: Servers

Data Compromised: Social security numbers
Brand Reputation Impact: Potential reputational harm due to exposure of sensitive personal data
Identity Theft Risk: High (due to exposure of Social Security numbers)
Commonly Compromised Data Types: The types of data most commonly compromised in incidents are Social Security Numbers and .

Entity Name: Gilead Sciences
Entity Type: Company
Industry: Pharmaceuticals

Entity Name: Gilead Sciences, Inc.
Entity Type: Corporation
Industry: Biopharmaceutical
Location: United States
Customers Affected: 12,224 individuals (including 4 residents in California)

Entity Name: Billing Document Specialists
Entity Type: Third-Party Vendor
Industry: Document Processing

Communication Strategy: Public disclosure via Maine Office of the Attorney General

Type of Data Compromised: Social security numbers
Number of Records Exposed: 12,224
Sensitivity of Data: High (Personally Identifiable Information)
Data Exfiltration: No (inadvertent disclosure via mailing error)
Personally Identifiable Information: Yes

Regulatory Notifications: Maine Office of the Attorney General

Source: Maine Office of the Attorney General
Date Accessed: 2025-04-02
Additional Resources: Stakeholders can find additional resources on cybersecurity best practices at and Source: Maine Office of the Attorney GeneralDate Accessed: 2025-04-02.
Communication of Investigation Status: The company communicates the status of incident investigations to stakeholders through Public disclosure via Maine Office of the Attorney General.

Entry Point: Fake Email Logins,

Root Causes: Human error by third-party vendor (Billing Document Specialists) leading to inadvertent disclosure of sensitive data via mail.
Last Attacking Group: The attacking group in the last incident was an Iran-Linked Hackers.
Most Recent Incident Detected: The most recent incident detected was on 2025-02-18.
Most Recent Incident Publicly Disclosed: The most recent incident publicly disclosed was on 2025-04-02.
Most Significant Data Compromised: The most significant data compromised in an incident were Social Security numbers and .
Most Significant System Affected: The most significant system affected in an incident was Servers.
Most Sensitive Data Compromised: The most sensitive data compromised in a breach was Social Security numbers.
Number of Records Exposed in Most Significant Breach: The number of records exposed in the most significant breach was 12.2K.
Most Recent Source: The most recent source of information about an incident is Maine Office of the Attorney General.
.png)
FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.
Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.
Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.
Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.
The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
